119 related articles for article (PubMed ID: 24685603)
21. Polymorphism in the thymidylate synthase promoter enhancer region and risk of colorectal adenomas.
Chen J; Kyte C; Chan W; Wetmur JG; Fuchs CS; Giovannucci E
Cancer Epidemiol Biomarkers Prev; 2004 Dec; 13(12):2247-50. PubMed ID: 15598787
[TBL] [Abstract][Full Text] [Related]
22. Thymidylate synthase polymorphisms and hematological cancer risk: a meta-analysis.
Weng Y; Zhang J; Tang X; Xie X; Chen G
Leuk Lymphoma; 2012 Jul; 53(7):1345-51. PubMed ID: 22166040
[TBL] [Abstract][Full Text] [Related]
23. Case-control analysis of thymidylate synthase polymorphisms and risk of lung cancer.
Shi Q; Zhang Z; Neumann AS; Li G; Spitz MR; Wei Q
Carcinogenesis; 2005 Mar; 26(3):649-56. PubMed ID: 15579479
[TBL] [Abstract][Full Text] [Related]
24. Meta-analysis of adiponectin polymorphisms and colorectal cancer risk.
Ye C; Wang J; Tan S; Zhang J; Li M; Sun P
Int J Med Sci; 2013; 10(9):1113-20. PubMed ID: 23869187
[TBL] [Abstract][Full Text] [Related]
25. Polymorphisms of thymidylate synthase gene 5'- and 3'-untranslated region and risk of gastric cancer in Koreans.
Yim DJ; Kim OJ; An HJ; Kang H; Ahn DH; Hwang SG; Oh D; Kim NK
Anticancer Res; 2010 Jun; 30(6):2325-30. PubMed ID: 20651387
[TBL] [Abstract][Full Text] [Related]
26. Thymidylate synthase promoter polymorphism, interaction with folate intake, and risk of colorectal adenomas.
Ulrich CM; Bigler J; Bostick R; Fosdick L; Potter JD
Cancer Res; 2002 Jun; 62(12):3361-4. PubMed ID: 12067974
[TBL] [Abstract][Full Text] [Related]
27. [Pharmacogenetic studies on the prediction of efficacy and toxicity of fluoropyrimidine-based adjuvant therapy in colorectal cancer].
Kralovánszky J; Adleff V; Hitre E; Pap E; Réti A; Komlósi V; Budai B
Magy Onkol; 2007; 51(2):113-25. PubMed ID: 17660867
[TBL] [Abstract][Full Text] [Related]
28. The association between two polymorphisms in the TYMS gene and breast cancer risk: a meta-analysis.
Wang J; Wang B; Bi J; Di J
Breast Cancer Res Treat; 2011 Jul; 128(1):203-9. PubMed ID: 21188629
[TBL] [Abstract][Full Text] [Related]
29. Thymidylate synthase gene promoter polymorphisms are associated with TSmRNA expressions but not with microsatellite instability in colorectal cancer.
Calascibetta A; Cabibi D; Martorana A; Sanguedolce G; Rausa L; Feo S; Dardanoni G; Sanguedolce R
Anticancer Res; 2004; 24(6):3875-80. PubMed ID: 15736425
[TBL] [Abstract][Full Text] [Related]
30. Thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase expression in colorectal cancer and normal mucosa in patients.
Amatori F; Di Paolo A; Del Tacca M; Fontanini G; Vannozzi F; Boldrini L; Bocci G; Lastella M; Danesi R
Pharmacogenet Genomics; 2006 Nov; 16(11):809-16. PubMed ID: 17047489
[TBL] [Abstract][Full Text] [Related]
31. Polymorphisms of thymidylate synthase in the 5'- and 3'-untranslated regions associated with risk of gastric cancer in South China: a case-control analysis.
Zhang Z; Xu Y; Zhou J; Wang X; Wang L; Hu X; Guo J; Wei Q; Shen H
Carcinogenesis; 2005 Oct; 26(10):1764-9. PubMed ID: 15930032
[TBL] [Abstract][Full Text] [Related]
32. Associations between polymorphisms in the thymidylate synthase gene, the expression of thymidylate synthase mRNA and the microsatellite instability phenotype of colorectal cancer.
Merkelbach-Bruse S; Hans V; Mathiak M; Sanguedolce R; Alessandro R; Rüschoff J; Büttner R; Houshdaran F; Gullotti L
Oncol Rep; 2004 Apr; 11(4):839-43. PubMed ID: 15010882
[TBL] [Abstract][Full Text] [Related]
33. An updated meta-analysis on the association of TGF-β1 gene promoter -509C/T polymorphism with colorectal cancer risk.
Wang Y; Yang H; Li L; Xia X
Cytokine; 2013 Jan; 61(1):181-7. PubMed ID: 23084539
[TBL] [Abstract][Full Text] [Related]
34. Polymorphisms of folate pathway enzymes (methylenetetrahydrofolate reductase and thymidylate synthase) and their relationship with thymidylate synthase expression in human astrocytic tumors.
da Costa DM; de Lima GP; Faria MH; Rabenhorst SH
DNA Cell Biol; 2012 Jan; 31(1):57-66. PubMed ID: 21848426
[TBL] [Abstract][Full Text] [Related]
35. Methylenetetrahydrofolate reductase polymorphisms and breast cancer risk: a meta-analysis from 41 studies with 16,480 cases and 22,388 controls.
Qi X; Ma X; Yang X; Fan L; Zhang Y; Zhang F; Chen L; Zhou Y; Jiang J
Breast Cancer Res Treat; 2010 Sep; 123(2):499-506. PubMed ID: 20135343
[TBL] [Abstract][Full Text] [Related]
36. Polymorphism in the thymidylate synthase promoter enhancer region in colorectal cancer.
Marsh S; McKay JA; Cassidy J; McLeod HL
Int J Oncol; 2001 Aug; 19(2):383-6. PubMed ID: 11445856
[TBL] [Abstract][Full Text] [Related]
37. Meta-analysis of the association between COX-2 polymorphisms and risk of colorectal cancer based on case-control studies.
Peng Q; Yang S; Lao X; Tang W; Chen Z; Lai H; Wang J; Sui J; Qin X; Li S
PLoS One; 2014; 9(4):e94790. PubMed ID: 24733273
[TBL] [Abstract][Full Text] [Related]
38. Lack of associations between XPC polymorphisms and colorectal cancer: a meta-analysis.
Wang G; Sun H; Liu Z; Huang R; Chen Y; Tang Q; Yu L; Jiang Z; Wang X
J BUON; 2015; 20(3):770-4. PubMed ID: 26214629
[TBL] [Abstract][Full Text] [Related]
39. Associations between polymorphisms within the thymidylate synthase gene and spina bifida.
Volcik KA; Shaw GM; Zhu H; Lammer EJ; Laurent C; Finnell RH
Birth Defects Res A Clin Mol Teratol; 2003 Nov; 67(11):924-8. PubMed ID: 14745930
[TBL] [Abstract][Full Text] [Related]
40. Association between rs11614913 polymorphism in miR-196a2 and colorectal cancer risk: a meta-analysis.
Du W; Ma X; Kong W; Liu T; Wei B; Yu J; Li Y; Huang J; Li Z; Liu L
Cancer Biomark; 2013 Jan; 13(6):457-64. PubMed ID: 24595083
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
